Two recent publications use Oncomine...

AGTR1 overexpression defines a subset of breast cancer and confers sensitivity to losartan, an AGTR1 antagonist.

Pubmed

A gene expression signature associated with "K-Ras addiction" reveals regulators of EMT and tumor cell survival.

Pubmed

28 APRIL 2009
...ANNOUNCES COLLABORATION WITH MDS PHARMA SERVICES TO DELIVER NOVEL SOLUTION FOR ONCOLOGY DRUG DEVELOPMENT

...announced a strategic collaboration with MDS Pharma Services to deliver OncoPredictor^SM — a novel solution for improved cancer drug development. OncoPredictor SM combines MDS Pharma Services OncoPanel™ with Compendia Bioscience’s Oncomine™ for a solution that will provide guidance on patient groups most likely to respond to a new cancer therapy.

READ MORE

Compendia Bioscience, Inc. is dedicated to gathering the world's high-throughput biology data, making that data interpretable and applicable in target identification/validation, drug development, and clinical research to ultimately improve the lives of patients.

Compendia Bioscience's flagship product, Oncomine™, integrates and unifies this data so that target expression across thousands of human tumors, hundreds of cancer types and subtypes, and millions of dollars of experiments can be assessed online in seconds. Oncomine enables users to discover and prioritize potential cancer targets and biomarkers, improving efficiency, strengthening product pipelines and increasing the likelihood of success.

Compendia provides product offerings for both research (non-profit) and commercial organizations.